Article Information
History
- August 10, 2016.
Article Versions
- You are currently viewing Version 1 of this article (August 10, 2016 - 15:05).
- Version 2 (August 14, 2016 - 17:25).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Mateusz Maciejewski, PhD1,*,
- Eugen Lounkine, PhD2,*,
- Steven Whitebread, BS2,
- Pierre Farmer, PhD3,
- Brian K. Shoichet, PhD4,* and
- Laszlo Urban, MD, PhD2,*
- 1Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, USA.
- 2Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
- 3Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
- 4University of California, San Francisco, San Francisco, California 94158, USA.
- ↵*Corresponding authors: Laszlo Urban, MD, PhD, Preclinical Secondary Pharmacology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA., 02139, U.S.A. e-mail: laszlo.urban{at}novartis.com; Mateusz Maciejewski, PhD, Inflammation & Immunology, Pfizer Inc., 610 Main Street, Cambridge, MA, 02139, U.S.A. e-mail: matt{at}mattmaciejewski.com; Eugen Lounkine, PhD, Center for Proteomic Chemistry, 250 Massachusetts Avenue, Cambridge, MA., 02139, U.S.A. e-mail:eugen.lounkine{at}novartis.com; Brian K. Shoichet, PhD, Dept. of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D CA., 94158-2550, U.S.A. e-mail:shoichet{at}cgl.ucsf.edu